Cell Death and Disease (Apr 2024)

FBXO32-mediated degradation of PTEN promotes lung adenocarcinoma progression

  • Jie Wu,
  • Ting Wen,
  • Antonio Marzio,
  • Dingli Song,
  • Sisi Chen,
  • Chengcheng Yang,
  • Fengyu Zhao,
  • Boxiang Zhang,
  • Guang Zhao,
  • Alessandra Ferri,
  • Hao Cheng,
  • Jiao Ma,
  • Hong Ren,
  • Qiao Yi Chen,
  • Yiping Yang,
  • Sida Qin

DOI
https://doi.org/10.1038/s41419-024-06635-4
Journal volume & issue
Vol. 15, no. 4
pp. 1 – 14

Abstract

Read online

Abstract FBXO32, a member of the F-box protein family, is known to play both oncogenic and tumor-suppressive roles in different cancers. However, the functions and the molecular mechanisms regulated by FBXO32 in lung adenocarcinoma (LUAD) remain unclear. Here, we report that FBXO32 is overexpressed in LUAD compared with normal lung tissues, and high expression of FBXO32 correlates with poor prognosis in LUAD patients. Firstly, we observed with a series of functional experiments that FBXO32 alters the cell cycle and promotes the invasion and metastasis of LUAD cells. We further corroborate our findings using in vivo mouse models of metastasis and confirmed that FBXO32 positively regulates LUAD tumor metastasis. Using a proteomic-based approach combined with computational analyses, we found a positive correlation between FBXO32 and the PI3K/AKT/mTOR pathway, and identified PTEN as a FBXO32 interactor. More important, FBXO32 binds PTEN via its C-terminal substrate binding domain and we also validated PTEN as a bona fide FBXO32 substrate. Finally, we demonstrated that FBXO32 promotes EMT and regulates the cell cycle by targeting PTEN for proteasomal-dependent degradation. In summary, our study highlights the role of FBXO32 in promoting the PI3K/AKT/mTOR pathway via PTEN degradation, thereby fostering lung adenocarcinoma progression.